Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients With Hematologic Malignancies
Primary end points are treatment-related mortality and engraftment. Secondary end points are
regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.
-Patients should have an unrelated donor who is matched for HLA-A and -B by serology and
for -DRB1 by molecular typing.
- Patients should not have major illness or organ failure
- Patients must not have a psychiatric disorder or mental deficiency severe as to make
compliance with the treatment unlike, and making informed consent impossible.
- Patients must not be pregnant or lactating.
Type of Study:
Observational Model: Case-Only, Time Perspective: Prospective
treatment-related mortality and engraftment
Outcome Time Frame:
all cause mortality
Kyoo-hyung Lee, doctor
Korea: Food and Drug Administration
- Hematologic Malignancies
- patients without comorbidity
- Hematologic Neoplasms